NautaDutilh provides truly integrated services to clients in the life sciences & healthcare sector. Our dedication to and focus on the pharma, biotech, medtech and healthcare industries has resulted in a broad recognition as go-to full-service advisor in the Benelux life sciences and healthcare industry; from top notch regulatory advice, to advising on the most complex Corporate M&A deals, financings and representing clients in high end IP and product liability litigation. Other services include advice on sector specific competition law issues, advertising regulations, data protection and government affairs, as well as other relevant areas of expertise (including employment, tax, real estate etc.).
We advise national and international clients in the healthcare, pharmaceutical, biotechnology and medical devices sectors, from start-ups to market leaders.
Thanks to our extensive experience and active participation in many large professional organisations (for example, HollandBio and flanders.bio) we have built a powerful network and have comprehensive knowledge of the sector. Our lawyers publish and speak regularly on subjects such as competition, intellectual property, and financing in the pharmaceutical, biotech and medical devices sectors.
NautaDutilh's Healthcare & Life Sciences team takes a holistic approach and is composed of lawyers from various practice groups (including regulatory, IP, public procurement, privacy, competition, M&A and finance specialists). This enables us to provide the full range of advisory, litigation and transactional services, tailored to meet our clients' needs at all stages of their product and business cycles: from a company’s incorporation, financing rounds and investment arrangements to acquisition by listed companies or another form of exit such as an IPO. For business operations we assist with contracting (including licensing), intellectual property related issues, risk management and compliance. As a result of our dedication and attention to the life sciences sector, we are now widely recognised among industry players as one of the go-to full-service advisers in the Benelux.
Our Healthcare &Life Sciences team advises both domestic and international clients – ranging from start-ups to industry leaders and academic research centers – in the pharmaceutical, biotechnology and medical devices fields, in transactional matters and dealings with the regulators and, if necessary, before the courts.
The Healthcare & Life Sciences team boasts the largest Dutch pharma deal (in size) ever: AstraZeneca's up to USD 7 billion acquisition of Acerta Pharma. They advised Batavia Biosciences on is auction sale to CJ, Onward Medical on is Euronext IPO, Cerba Healthcare on its acquisition of Viroclinics, NewAmsterdam Pharma on its de-SPAC transaction with Frazier Healthcare and Gingko Bioworks on its acquisition of Dutch DNA.
They have also performed ongoing venture capital work concerning various successful biotech, pharma, agrotech and medical devices companies. At the same time, it provides high-end regulatory and litigation services with regard to product launches and distribution, advertising, clinical trials, generic entry, patent litigation and product liability issues, to name a few.
We work for a number of reputable life sciences companies and investors such as Abacus Medicine, Allergan, AstraZeneca, Azalea Vision, Bausch Health companies Inc., Eagle Pharmaceuticals, EQT Life Sciences, Gadeta, Gilead, Forbion Growth GlaxoSmithKline, Illumina, Imcyse, Incyte, InflaRx, Mediq, Merus, Morrow, Nyxoah, Onward Medical, Pfizer, Pharming, Sanofi, and Vico Therapeutics International.
Our client portfolio also includes various investment banks involved in IPOs and capital market transactions, such as Cowen and Company, Kempen & Co, Jefferies LLC, SVB Leerink, Piper Jaffray & Co, UBC and Wedbush Securities.
Our Track records